Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies Published September 2019 Citation Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR. . ESMO Annual Congress. . https://www.annalsofoncology.org/article/S0923-7534(19)59501-1/pdf Authors:Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR Sources:ESMO Annual Congress Share Posted inPublicationsComparative effectivenessMelanoma More publicationsASCO Annual MeetingMay 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancerGanti AK, Snider J, Yan J, et al.Publication summaryPublicationsComparative effectivenessSmall cell lung cancerGynecologic OncologyDecember 2025Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)Shahin M, Mathur R, Parthan A, et al.Real-world evidencePublication summaryPublicationsComparative effectivenessOvarian cancerESMOOctober 2025Treatment duration and subsequent treatments of first-line CDK4/6i plus aromatase inhibitor for HR+/HER2- metastatic breast cancer in US routine clinical practiceBrufsky A, Layman R, Liu X, et al.Publication summaryPublicationsComparative effectivenessBreast cancer